0
Your cart

Your cart is empty

Books > Professional & Technical > Industrial chemistry & manufacturing technologies > Industrial chemistry > Pharmaceutical technology

Buy Now

The Challenge of CMC Regulatory Compliance for Biopharmaceuticals (Hardcover, 3rd ed. 2019) Loot Price: R4,606
Discovery Miles 46 060
The Challenge of CMC Regulatory Compliance for Biopharmaceuticals (Hardcover, 3rd ed. 2019): John Geigert

The Challenge of CMC Regulatory Compliance for Biopharmaceuticals (Hardcover, 3rd ed. 2019)

John Geigert

 (sign in to rate)
Loot Price R4,606 Discovery Miles 46 060 | Repayment Terms: R432 pm x 12*

Bookmark and Share

Expected to ship within 12 - 19 working days

Biopharmaceuticals (i.e., biological medicines sourced from genetically-engineered living systems) for treatment of human diseases have become a significant percentage of the pharmaceutical industry. And not just the recombinant DNA-derived proteins and monoclonal antibodies (both from the innovators and biosimilars); but now, an increasing awareness of the importance of gene therapy and genetically engineered cellular medicinal products. These biopharmaceuticals are being developed by many companies whose Chemistry, Manufacturing & Control (CMC) teams have varying degrees of familiarity or experience with the CMC strategy and regulatory compliance requirements for these challenging products. Companies clearly plan out the strategy for their clinical study plans, but frequently, the development of a strategy for CMC is an afterthought. Coupled with the complexity of the biopharmaceutical manufacturing processes and products, and this can be a recipe for disaster. The third edition of this book provides insights and practical guidance for the CMC teams to develop an acceptable cost-effective, risk-based CMC regulatory compliance strategy for all biopharmaceuticals (recombinant proteins, monoclonal antibodies, genetically engineered viruses and genetically engineered human cells) from early clinical stage development through market approval. The third edition of this book provides added coverage for the biosimilars, antibody drug conjugates (ADCs), bispecific antibodies, genetically engineered viruses, and genetically engineered cells. This third edition of the book also addresses the heightened pressure on CMC regulatory compliance timelines due to the introduction of expedited clinical pathways moving the clinical development closer to a seamless phase process (e.g., FDA Breakthrough Therapy designation, CBER Regenerative Medicine Advanced Therapy (RMAT) designation, EMA Priority Medicines (PRIME) designation). The Challenge of CMC Regulatory Compliance for Biopharmaceuticals is essential, practical information for all pharmaceutical development scientists, Manufacturing and Quality Unit staff, Regulatory Affairs personnel, and senior management involved in the manufacture of biopharmaceuticals.

General

Imprint: Springer Nature Switzerland AG
Country of origin: Switzerland
Release date: May 2019
First published: 2019
Authors: John Geigert
Dimensions: 235 x 155mm (L x W)
Format: Hardcover
Pages: 426
Edition: 3rd ed. 2019
ISBN-13: 978-3-03-013753-3
Categories: Books > Medicine > General issues > Medical equipment & techniques > Medical research
Books > Professional & Technical > Industrial chemistry & manufacturing technologies > Industrial chemistry > Pharmaceutical technology
Promotions
LSN: 3-03-013753-8
Barcode: 9783030137533

Is the information for this product incomplete, wrong or inappropriate? Let us know about it.

Does this product have an incorrect or missing image? Send us a new image.

Is this product missing categories? Add more categories.

Review This Product

No reviews yet - be the first to create one!

You might also like..

Modern Approaches in Drug Discovery…
Charles Lesburg Hardcover R4,579 Discovery Miles 45 790
Drug Delivery Nanosystems for Biomedical…
Chandra P Sharma Hardcover R4,054 R3,777 Discovery Miles 37 770
Quantitative Systems Pharmacology…
Davide Manca Hardcover R5,765 R5,328 Discovery Miles 53 280
Handbook of Cosmeceutical Excipients and…
Y H Kwan, Y K Tung, … Hardcover R4,005 Discovery Miles 40 050
Therapeutic Risk Management of Medicines
Stephen J. Mayall, Anjan Swapu Banerjee Hardcover R4,851 Discovery Miles 48 510
Orphan Drugs - Understanding the Rare…
Elizabeth Hernberg-Stahl, Miroslav Reljanović Hardcover R4,474 Discovery Miles 44 740
Lean Biomanufacturing - Creating Value…
Nigel J. Smart Hardcover R4,487 Discovery Miles 44 870
Formulation Tools for Pharmaceutical…
J. E. Aguilar Hardcover R4,029 Discovery Miles 40 290
Computer-Aided Applications in…
Jelena Duris Hardcover R3,542 Discovery Miles 35 420
Therapeutic Protein Drug Products…
Brian K. Meyer Hardcover R3,650 Discovery Miles 36 500
Intelligent Materials for Controlled…
Steven M Dinh, John DeNuzzio, … Hardcover R2,470 Discovery Miles 24 700
The Biochemistry of Drug Metabolism…
B. Testa Paperback R2,344 R1,920 Discovery Miles 19 200

See more

Partners